Oramorph dose and clinical guidance for 2025 supports safe prescribing
Oral morphine sulphate supplied as Oramorph remains a first-line strong opioid when moderate to severe pain does not respond to weaker agents. The immediate release formulation supports fast onset, short duration, and close titration to effect. In the United Kingdom, licensed use focuses on severe pain in cancer and at the end of life, with […]